Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VBI Vaccines Inc.    VBIV   CA91822J1030

VBI VACCINES INC.

(VBIV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The share is getting closer to its long-term support in weekly data, at USD 1.89, which offers good timing for buyers.
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 1.89 USD
Weaknesses
  • The company has insufficient levels of profitability.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's earnings releases usually do not meet expectations.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
VBI VACCINES INC.114.49%684
LONZA GROUP AG60.36%45 446
SEATTLE GENETICS, INC.66.73%33 148
IQVIA HOLDINGS INC.0.52%29 706
CELLTRION, INC.40.88%29 181
MODERNA, INC.260.69%27 838
IMMUNOMEDICS, INC.304.16%19 783
INCYTE CORPORATION3.48%19 762
ALNYLAM PHARMACEUTICALS, IN..21.39%16 214
HANGZHOU TIGERMED CONSULTIN..59.27%12 821
PPD, INC.0.00%11 992
QIAGEN N.V.52.40%11 783
PHARMARON BEIJING CO., LTD.92.08%11 175
CHARLES RIVER LABORATORIES ..41.90%11 099
ICON PUBLIC LIMITED COMPANY8.02%9 791
BIO-TECHNE CORPORATION11.04%9 398
More Results
Financials (USD)
Sales 2020 1,31 M - -
Net income 2020 -38,2 M - -
Net Debt 2020 - - -
P/E ratio 2020 -16,2x
Yield 2020 -
Capitalization 684 M 684 M -
Capi. / Sales 2020 524x
Capi. / Sales 2021 102x
Nbr of Employees 124
Free-Float 72,5%
Upcoming event on VBI VACCINES INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes